ProCE Banner Activity

My Take on the Recent Approval of Tazemetostat for Relapsed/Refractory Follicular Lymphoma

Clinical Thought
How will you incorporate tazemetostat, an EZH2 inhibitor, into your clinical practice for patients with relapsed/refractory follicular lymphoma? Here are my thoughts.

Released: August 04, 2020

Expiration: August 03, 2021

No longer available for credit.

Share

Faculty

John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Celgene

Epizyme, Inc.

Faculty Disclosure

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD, has disclosed that he received consulting fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, Epizyme, Kura, MorphoSys, Roche/Genentech, and Verastem and fees for non-CME/CE services from Seattle Genetics.